Studies of the intestinal metabolism of oral gold.
In order to understand some of the unique toxic/therapeutic properties of the orally administered gold containing compound auranofin, the intestinal metabolism of gold was studied in 4 normal subjects. A triple lumen intestinal perfusion apparatus was used to measure intestinal flux using a non-absorbable radiolabelled marker dilution technique. Over a short (50 cm) segment of proximal small bowel, substantial disappearance of gold was observed; the findings, however, were most consistent with a loose, reversible adsorption onto the enteric cell surface rather than true trans-mucosal absorption. There was no evidence for an entero-hepatic recirculation of gold in these subjects or in 4 additional patients with rheumatoid arthritis studied in a similar manner.
D000284:Administration, Oral; D000328:Adult; D001310:Auranofin; D006051:Aurothioglucose / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006046:Gold / Q000031:analogs & derivatives*; D006801:Humans; D007408:Intestinal Absorption; D007413:Intestinal Mucosa / Q000378:metabolism; D007421:Intestine, Small / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010477:Perfusion; D010720:Phosphines / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors
D010720:Phosphines; D006051:Aurothioglucose; D001310:Auranofin; D006046:Gold